Key result
FHL2 silencing reduced osteosarcoma tumor volume by approximately 2-fold and markedly decreased lung metastasis in mice by attenuating Wnt/β-catenin signaling.
Population
Human and murine osteosarcoma cells, human tissue microarrays, and female BALB/c mice injected with K7M2…
Comparison
FHL2 silencing using short hairpin RNA (shRNA) vs Non-relevant control shRNA
Design
Preclinical
Follow-up
6 weeks
Authors
Loading...
Supports FHL2 targeting in osteosarcoma models; leaves open clinical translation pending human studies.
p-value: p=<0.05
FHL2 silencing reduces Wnt signaling, osteosarcoma cell growth, and metastasis in vitro and in vivo, identifying FHL2 as a potential therapeutic target for primary bone tumors.
Brun et al. (2013) studied Osteosarcoma. FHL2 silencing via shRNA vs. Control shRNA was evaluated on Tumor volume and lung metastasis occurrence (p=<0.05). FHL2 silencing reduced osteosarcoma tumor volume by approximately 2-fold and markedly decreased lung metastasis in mice by attenuating Wnt/β-catenin signaling.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: